DSM-IV

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Retrieved on: 
Wednesday, November 1, 2023
Cream, Desire, Female, FDA, Trial of the century, SST, Food, Diagnostic and Statistical Manual of Mental Disorders, Endpoint, Diagnosis, DSM-IV codes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pelvic floor dysfunction, Embarrassment, Guilt, Female sexual arousal disorder, Arousal, FSAD, Woman, DSM-IV, PRO, Pharmaceutical industry

The Phase 2b RESPOND study enrolled women with FSAD and included women who had sexual dysfunctions in addition to FSAD.

Key Points: 
  • The Phase 2b RESPOND study enrolled women with FSAD and included women who had sexual dysfunctions in addition to FSAD.
  • In addition, only the Sildenafil Cream treatment group in this subset, and not the placebo group, demonstrated clinically meaningful improvement at the end of the 12-week period.
  • “The further analyses bolster our belief that Sildenafil Cream has the potential to successfully address the significant unmet need of arousal disorder.
  • The Phase 3 study design for Sildenafil Cream, including primary and secondary efficacy endpoints and inclusion/exclusion criteria for study participants, will be determined following discussions with the U.S. Food and Drug Administration (FDA), including the company’s end of Phase 2 meeting with the FDA.

Obsessive-Compulsive Disorder (OCD) Epidemiology Outlook 2023-2032: Prevalence, Diagnosis, and Forecast

Retrieved on: 
Friday, July 28, 2023
Pharmaceutical, Health, Mental Health, EU4, Prevalence, OCD, Tic disorder, Disorder, Epidemiology, Obsessions, Obsessive–compulsive disorder, HIV disease progression rates, Patient, Yale–Brown Obsessive Compulsive Scale, Diagnosis, DSM-5, Y-BOCS, Pharmaceutical industry, Dentistry, DSM-IV

The "Obsessive-Compulsive Disorder - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Obsessive-Compulsive Disorder - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Obsessive-compulsive disorder (OCD) has gained significant attention in the DSM-5, where it now has its own chapter.
  • The report offers a 10-year forecast and comprehensive coverage of the 7MM countries, with a detailed epidemiology segmentation for OCD.
  • The report provides valuable insights into the epidemiology of obsessive-compulsive disorder, including prevalence, diagnosis, and forecasts in the 7MM countries.

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Retrieved on: 
Tuesday, July 11, 2023
Cream, Desire, KOL, SST, Obstetrics, North American Menopause Society, Orgasm, International Society of Sculptors, Painters and Gravers, Diagnosis, FSAD, OBGYN, DSM-IV, NAMS, Woman, FACOG, Doctor of Philosophy, EDT, Trial of the century, NCMP, University Hospitals Cleveland Medical Center, Arousal, Medical director, Diagnostic and Statistical Manual of Mental Disorders, SAN, CCD, Gynaecology, Behavioral medicine, Erectile dysfunction, FDA, ITT, George Washington University, Female, Medical device, Management, Pharmaceutical industry

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced additional positive data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD). Additional data reported today support continued clinical development of Sildenafil Cream to evaluate its potential to treat FSAD and/or female sexual interest/arousal disorder (FSIAD). Specifically, an exploratory endpoint regarding sexual desire demonstrated a statistically significant improvement from baseline to the 8-week mark after randomization in women in the intent to treat (ITT) population who used Sildenafil Cream compared to placebo, at P value = 0.022. The improvement in sexual desire at the 8-week mark compared to baseline in the Sildenafil Cream ITT group persisted through 12 weeks post-randomization (end of study).

Key Points: 
  • Additional data reported today support continued clinical development of Sildenafil Cream to evaluate its potential to treat FSAD and/or female sexual interest/arousal disorder (FSIAD).
  • The improvement in sexual desire at the 8-week mark compared to baseline in the Sildenafil Cream ITT group persisted through 12 weeks post-randomization (end of study).
  • “In this study, improvement was seen in arousal and orgasm, as well as sexual desire.
  • Daré will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT to review data from the exploratory Phase 2b RESPOND clinical study.

LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Featuring Eli Lilly, Pfizer, Johnson & Johnson, Novartis & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Health, Pharmaceutical, DSM-IV, Caffeine, Amphetamine, Boston Children's Hospital, Hospital pharmacy, Guanfacine, Country, Safety, Methylphenidate, Hospital, Organization, Clonidine, Adderall, ADHD, Patient, Prevalence, Distribution, Pharmaceutical industry, Lisdexamfetamine

Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.

Key Points: 
  • Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood.
  • This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation.
  • The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028.
  • Additionally, The UAE market would register a CAGR of 7% during (2022-2028).

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

The First Real Mood Ring: Happy Health Launches The First Wearable Designed For Your Mind

Retrieved on: 
Wednesday, August 24, 2022
CEO, Technology, Heart rate, Washington Apple Health, Awareness, Platinum, Entrepreneurship, DSM-IV, Temperature, Peripheral nervous system, Habit, Health, Structured Clinical Interview for DSM-IV, Sympathetic nervous system, EDA, Water, Therapy, Mental health, Clinical Science (journal), Founder, American Psychiatric Association, American, Sleep, Pharmaceutical industry, Medical device, Happiness, Freckleton, Tinder

AUSTIN, Texas, Aug. 24, 2022 /PRNewswire/ -- Happy Health is a mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable designed to measure your stress and mood 24/7. Happy Health was co-founded by Sean Rad, Dustin Freckleton, Sue Smalley, Paul Berns, and Robert Nelsen. Today, Happy Health announces a $60M series-A round led by ARCH Venture Partners.

Key Points: 
  • AUSTIN, Texas, Aug. 24, 2022 /PRNewswire/ -- Happy Health is a mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable designed to measure your stress and mood 24/7.
  • Happy Health launches the first wearable designed for your mind and $60M in funding.
  • In his role at Happy Health, Dr. Hudziak has helped lead the team towards objective, real-time, real-world measures of stress and emotional health.
  • Happy Health is an Austin, TX-based mission-driven technology company committed to transforming mental health awareness through the Happy Ring, the first wearable for your mind, measuring your stress and mood 24/7.